Search the Newsreel

Exelon Adds Public Grid and Buckstop to 2c2i Portfolio, Advancing Affordable and Sustainable Energy Solutions

CHICAGO, August 11, 2026--(BUSINESS WIRE)--The Exelon Foundation has added two new companies to its Climate Change Investment Initiative (2c2i) portfolio: Public Grid and Buckstop. The investments reflect Exelon's commitment to supporting solutions that improve affordability, make better use of resources and contribute to a …

Exelon Backs a Platform Connecting Residents to Energy-Saving Programs

The Exelon Foundation has invested in Public Grid and Buckstop through its Climate Change Investment Initiative (2c2i). Public Grid connects residents to energy-saving programs through multifamily housing, aiming to reduce costs and promote efficient energy use. Buckstop focuses on recovering value from existing materials …

Crexendo Cloud Platform Adds About 1M Users Worldwide in 8 Months

Crexendo (NASDAQ: CXDO) announced that its AI-enhanced UCaaS cloud communications platform now supports over 8 million users worldwide, an increase of approximately one million users since late 2025. The platform's user base has grown over 370% since the June 2021 acquisition of NetSapiens. The …

MarketAxess' (MKTX) "Market Perform" Rating Reaffirmed at Keefe, Bruyette & Woods

Keefe, Bruyette & Woods reaffirmed a "Market Perform" rating for MarketAxess (MKTX) and raised its price target from $150 to $167, suggesting a 2.77% upside. This comes as MarketAxess exceeded Q2 earnings expectations with $1.95 EPS and $218.41 million in revenue, despite a slight …

H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy

H.C. Wainwright maintained a Buy rating and a $74.00 price target for Xenon Pharmaceuticals (NASDAQ: XENE), citing the FDA's lack of concerns regarding their pre-NDA meeting and the company's belief that their drug package supports approval of all four doses. The stock has seen …

HC Wainwright Issues Positive Outlook for XENE Earnings

HC Wainwright has revised its earnings outlook for Xenon Pharmaceuticals (NASDAQ:XENE), predicting reduced losses for Q3 2026 and subsequent fiscal years, and maintaining a "Buy" rating with a $74 price target. The biopharmaceutical company recently surpassed analyst expectations for its quarterly loss. Despite these …

Keefe Bruyette & Woods Downgrades MarketAxess to Market Perform From Outperform, Adjusts PT to $167 From $150

Keefe Bruyette & Woods has downgraded MarketAxess Holdings Inc. (MKTX) from Outperform to Market Perform. The firm also adjusted its price target for MarketAxess shares to $167, a slight increase from the previous target of $150. This rating change suggests a more neutral outlook …

Gpixel Changchun Microelectronics Sets Board Meeting to Review Interim Results and Dividend

Marketaxess Holdings Inc (MKTX) Stock News Today

Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

MARKETAXESS HOLDINGS INC. : KBW CUTS TO MARKET PERFORM FROM OUTPERFORM; RAISES TARGET PRICE TO $167 FROM $150

KBW has downgraded MarketAxess Holdings Inc. (MKTX.O) from "Outperform" to "Market Perform." Despite the downgrade, the investment firm has increased its target price for the company to $167 from $150. This adjustment reflects KBW's revised outlook on MarketAxess Holdings.

Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss

Xencor (XNCR) recently reported a narrower quarterly net loss, reinforcing positive sentiment and leading to significant share price returns over the last month and year. Despite negative 3- and 5-year returns, the company is considered 24.3% undervalued with a fair value of $28.50 compared …

Nexxen to Stream Three Executive Fireside Chats Online

Nexxen International Ltd. announced that its executive management and investor relations teams will participate in three upcoming financial conferences: the Canaccord Genuity Annual Growth Conference on August 12, the Rosenblatt Annual Technology Summit on August 18, and the Citi Global TMT Conference on September …

MarketAxess (MKTX) General Counsel Scott Pintoff Sells 100 Shares

MarketAxess (MKTX) General Counsel Scott Pintoff sold 100 shares at $162.60, part of a pattern of 11 insider sales and zero buys over the past year. Despite this insider selling, MarketAxess is deemed "Significantly Undervalued" by GuruFocus's GF Value model, with a price-to-GF-Value ratio …

Exelon's MidAtlantic Utilities Face Challenges to Serve Data Center Growth

Exelon's MidAtlantic utilities are facing challenges in meeting the increasing demand for power from data centers, an issue that is causing investor concern. This report from Morningstar analyst Andrew Bischof highlights the difficulties for the pure-play electric and gas transmission and distribution utility. Previous …

What’s Behind Xenia Hotels & Resorts (XHR) Stock’s Latest Move?

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …

MarketAxess (NASDAQ:MKTX) General Counsel Sells $16,260.00 in Stock

MarketAxess General Counsel Scott Pintoff sold 100 shares of MKTX stock for $16,260.00, reducing his total holdings to 11,586 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $0.78 per share. Despite the insider sale, analysts …

Radian Group appoints Deluxe CEO Barry McCarthy to board By Investing.com

Radian Group Inc. has announced the appointment of Barry C. McCarthy, CEO of Deluxe Corporation, to its Board of Directors. McCarthy brings nearly four decades of executive leadership experience in financial services, payments, data, and technology. His appointment is expected to add valuable expertise …

EXELIXIS, INC. SEC Filing (Aug 10, 2026)

This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …

Crexendo posts investor presentation to website under Regulation FD

Crexendo (CXDO) announced it has posted an investor presentation on its investor relations website, www.crexendo.com

MarketAxess (MKTX) investor files to sell 300 shares after recent sales

Scott Pintoff, an investor in MarketAxess Holdings Inc. (MKTX), has filed a Form 144 notice to sell 300 shares of common stock through Charles Schwab & Co., Inc. The proposed sale date is August 10, 2026, and the shares are related to RSU/PSU equity …

Weekly Recap: ICE to acquire MarketAxess $6B and ADV & OI gains

Intercontinental Exchange, Inc. (ICE) plans to acquire MarketAxess for approximately $6 billion, driven by a significant surge in core trading volumes, with ADV and OI increasing by around 39% and 38% respectively. This growth is largely attributed to gains in interest-rate venues. Additionally, ICE …

Exelon Corp. stock underperforms Monday when compared to competitors

Exelon Corp. (EXC) stock fell 2.43% to $44.50 on Monday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. The company's shares closed 12.14% below their 52-week high of $50.65.

Form 8K Crexendo For: 10 August By Investing.com

This article reports on a Form 8K filing by Crexendo for August 10th. The brief piece includes the company's stock symbol CXDO and its current performance of +2.06%. It also shows general market data for various indices, commodities, bonds, and shares.

Axera Semiconductor Accelerates Edge AI Push as Revenue Surges but Losses Deepen

Axera Semiconductor to Fund Up to RMB70 Million H-Share Awards Buyback

Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average "Buy" rating from nine brokerage firms, with an average 12-month price target of $18.75. Despite insider sales totaling $280,089 over the past three months, institutional investors collectively own 60.67% of the company. The company's stock currently …

(EXEL) as a Liquidity Pulse for Institutional Tactics

This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal …

Assenagon Asset Management S.A. Has $23.57 Million Stake in Exelon Corporation $EXC

Assenagon Asset Management S.A. significantly increased its stake in Exelon Corporation by 133.9% in the second quarter, bringing its total holdings to 505,564 shares valued at $23.57 million. Despite this, institutional investors collectively own 80.92% of Exelon, while analyst sentiment remains cautious with a …

Brokers Issue Forecasts for XENE Q1 Earnings

Crexendo: Positive Q2 Results And Outlook Could Drive Strong Stock Gains (NASDAQ:CXDO)

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

Quantinno Capital Management LP significantly increased its stake in Xenon Pharmaceuticals Inc. by 125.1% in the first quarter, acquiring an additional 30,816 shares. The biopharmaceutical company, which has no product sales, reported a narrower-than-expected quarterly loss of $1.11 per share. Analyst sentiment remains largely …

Exelon (EXC) Could Be 8% Undervalued Following Second Quarter Earnings

Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results

Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. …